8-K 1 d8k.txt FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ---------- FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(D) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 29, 2003 ANTARES PHARMA, INC. --------------------- (Exact Name of Registrant as Specified in Charter) Minnesota 0-20945 41-1350192 --------- ------- ---------- (State or Other (Commission (I.R.S. Employer Jurisdiction File Number) Identification No.) of Incorporation) 707 Eagleview Boulevard, Suite 414, Exton, PA 19341 -------------------------------------------------------- (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (610) 458-6200 Not Applicable ------------------------------------------------------------- (Former Name or Former Address, if Changed Since Last Report) Item 9. Regulation FD Disclsoure. On May 29, 2003, Antares Pharma, Inc. issued a press release regarding its presentation at the Friedman Billings Ramsey 7th Annual Technology and Growth Investor Conference. A copy of the press release issued is attached hereto as Exhibit 99.1 Item 7. Financial Statements, Pro Forma Financial Information and Exhibits. (c) Exhibits. 99.1 Press Release dated May 29, 2003. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 29, 2003 ANTARES PHARMA, INC. By /s/ Lawrence M. Christian ---------------------------- Lawrence M. Christian Chief Financial Officer EXHIBIT INDEX 99.1 Press Release dated May 29, 2003.